ReviewClinical and experimental immunology2005
Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens.
Review in Clinical and experimental immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma.Gene therapy · 2011Trial
- Synthetic T-Cell Receptor-like Protein Behaves as a Janus Particle in Solution.Journal of the American Chemical Society · 2025Article
- Engineering soluble T-cell receptors for therapy.The FEBS journal · 2021Review
- Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors.Nanoscale · 2021Article
- CD8+ T cells produce a dialyzable antigen-specific activator of dendritic cells.Journal of leukocyte biology · 2017Article
- A pharmacologic perspective on newly emerging T-cell manipulation technologies.British journal of clinical pharmacology · 2013Review
- Antigen potency and maximal efficacy reveal a mechanism of efficient T cell activation.Science signaling · 2011Article
- Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Archivum immunologiae et therapiae experimentalis · 2010Review
- Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.Cancer immunology, immunotherapy : CII · 2010Article
- Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins.BMC biotechnology · 2010Article
- Combinations of affinity-enhancing mutations in a T cell receptor reveal highly nonadditive effects within and between complementarity determining regions and chains.Biochemistry · 2010Article
- Engineering higher affinity T cell receptors using a T cell display system.Journal of immunological methods · 2008Article
- Display technologies: application for the discovery of drug and gene delivery agents.Advanced drug delivery reviews · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent development of T cell receptor phage display opens up the possibility of engineering human T cell receptors with antibody-like binding properties for cell-surface peptide antigens. In this review we briefly discuss recent developments in molecular targeting of peptide antigens. We then discuss potential clinical applications of engineered high-affinity T cell receptors in autoimmunity and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.